Ability of traditional lipid ratios and apolipoprotein ratios to predict cardiovascular risk in people with type 2 diabetes

[1]  John B Buse,et al.  Effects of combination lipid therapy in type 2 diabetes mellitus. , 2010, The New England journal of medicine.

[2]  A. Sniderman.  Apolipoprotein B, Diabetes and Medical Consensus , 2010, Annals of clinical biochemistry.

[3]  R. Rosenson.  Management of non-high-density lipoprotein abnormalities. , 2009, Atherosclerosis.

[4]  A. Sniderman.  Targets for LDL-lowering therapy , 2009, Current opinion in lipidology.

[5]  Sridevi Devaraj,et al.  Apolipoprotein B and cardiovascular disease risk: position statement from the AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices. , 2009, Clinical chemistry.

[6]  P. Ridker,et al.  Prognostic Utility of ApoB/AI, Total Cholesterol/HDL, Non-HDL Cholesterol, or hs-CRP as Predictors of Clinical Risk in Patients Receiving Statin Therapy After Acute Coronary Syndromes: Results From PROVE IT–TIMI 22 , 2009, Arteriosclerosis, thrombosis, and vascular biology.

[7]  Donald A. Smith,et al.  Advanced lipoprotein testing: recommendations based on current evidence. , 2009, Endocrinology and metabolism clinics of North America.

[8]  A. Mooradian.  Dyslipidemia in type 2 diabetes mellitus , 2009, Nature Clinical Practice Endocrinology &Metabolism.

[9]  G. Hitman,et al.  Apolipoproteins, cardiovascular risk and statin response in type 2 diabetes: the Collaborative Atorvastatin Diabetes Study (CARDS) , 2009, Diabetologia.

[10]  Jennifer G. Robinson,et al.  Meta-analysis of the relationship between non-high-density lipoprotein cholesterol reduction and coronary heart disease risk. , 2009, Journal of the American College of Cardiology.

[11]  Executive Summary: Standards of Medical Care in Diabetes—2009 , 2009, Diabetes Care.

[12]  B. Nordestgaard,et al.  Fasting and Nonfasting Lipid Levels: Influence of Normal Food Intake on Lipids, Lipoproteins, Apolipoproteins, and Cardiovascular Risk Prediction , 2008, Circulation.

[13]  A. Keech,et al.  Effects of Fenofibrate Treatment on Cardiovascular Disease Risk in 9,795 Individuals With Type 2 Diabetes and Various Components of the Metabolic Syndrome , 2008, Diabetes Care.

[14]  M. Davidson.  Is LDL-C passed its prime? The emerging role of non-HDL, LDL-P, and ApoB in CHD risk assessment. , 2008, Arteriosclerosis, thrombosis, and vascular biology.

[15]  M. Blaha,et al.  The importance of non-HDL cholesterol reporting in lipid management. , 2008, Journal of clinical lipidology.

[16]  Steven Hawken,et al.  Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study , 2008, The Lancet.

[17]  L. Lind.  Apolipoprotein B/A1 and risk of cardiovascular disease , 2008, The Lancet.

[18]  Anders G. Olsson,et al.  Lipids, Apolipoproteins, and Their Ratios in Relation to Cardiovascular Events With Statin Treatment , 2008, Circulation.

[19]  E. Schaefer,et al.  Relative atherogenicity and predictive value of non-high-density lipoprotein cholesterol for coronary heart disease. , 2008, The American journal of cardiology.

[20]  Curt D. Furberg,et al.  Lipoprotein Management in Patients With Cardiometabolic Risk , 2008, Diabetes Care.

[21]  R. Krauss,et al.  The editor's roundtable: expanded versus standard lipid panels in assessing and managing cardiovascular risk. , 2008, The American journal of cardiology.

[22]  O. Faergeman,et al.  Lipoprotein predictors of cardiovascular events in statin-treated patients with coronary heart disease. Insights from the Incremental Decrease in End-points through Aggressive Lipid-lowering Trial (IDEAL) , 2008, Annals of medicine.

[23]  M. Faraj,et al.  Apolipoprotein B, apolipoprotein A-I, insulin resistance and the metabolic syndrome , 2007, Current opinion in lipidology.

[24]  Michael J Pencina,et al.  LDL Particle Number and Risk of Future Cardiovascular Disease in the Framingham Offspring Study - Implications for LDL Management. , 2007, Journal of clinical lipidology.

[25]  R. Luben,et al.  Apolipoprotein A-II Is Inversely Associated With Risk of Future Coronary Artery Disease , 2007, Circulation.

[26]  M. Pencina,et al.  Clinical utility of different lipid measures for prediction of coronary heart disease in men and women. , 2007, JAMA.

[27]  B. Nordestgaard,et al.  Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. , 2007, JAMA.

[28]  A. Zwinderman,et al.  Role of the Apolipoprotein BApolipoprotein A-I Ratio in Cardiovascular Risk Assessment: A CaseControl Analysis in EPIC-Norfolk , 2007, Annals of Internal Medicine.

[29]  A. Sniderman.  Low-density lipoprotein lowering in type 2 diabetes mellitus: how to know how low to go , 2007, Current opinion in endocrinology, diabetes, and obesity.

[30]  Nicholas J Wareham,et al.  Value of low-density lipoprotein particle number and size as predictors of coronary artery disease in apparently healthy men and women: the EPIC-Norfolk Prospective Population Study. , 2007, Journal of the American College of Cardiology.

[31]  G. Watts,et al.  Apolipoproteins as markers and managers of coronary risk. , 2006, QJM : monthly journal of the Association of Physicians.

[32]  J. Danesh,et al.  Associations between apolipoprotein B, apolipoprotein AI, the apolipoprotein B/AI ratio and coronary heart disease: a literature‐based meta‐analysis of prospective studies , 2006, Journal of internal medicine.

[33]  P. Barter,et al.  The rationale for using apoA‐I as a clinical marker of cardiovascular risk , 2006, Journal of internal medicine.

[34]  P. Durrington,et al.  Apolipoproteins AI and B as therapeutic targets , 2006, Journal of internal medicine.

[35]  H. Bloomfield,et al.  Low-Density Lipoprotein and High-Density Lipoprotein Particle Subclasses Predict Coronary Events and Are Favorably Changed by Gemfibrozil Therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial , 2006, Circulation.

[36]  R. Krauss,et al.  Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty‐person/ten‐country panel , 2006, Journal of internal medicine.

[37]  M. Denke.  Weighing in before the fight: low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol versus apolipoprotein B as the best predictor for coronary heart disease and the best measure of therapy. , 2005, Circulation.

[38]  P Glasziou,et al.  Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial , 2005, The Lancet.

[39]  M. Taskinen.  Type 2 diabetes as a lipid disorder. , 2005, Current molecular medicine.

[40]  Nader Rifai,et al.  Non-HDL cholesterol and apolipoprotein B predict cardiovascular disease events among men with type 2 diabetes. , 2004, Diabetes care.

[41]  J. Cleeman,et al.  Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[42]  P. Ridker,et al.  Low-Density Lipoprotein Particle Concentration and Size as Determined by Nuclear Magnetic Resonance Spectroscopy as Predictors of Cardiovascular Disease in Women , 2002, Circulation.

[43]  J. Després,et al.  Effects of micronized fenofibrate versus atorvastatin in the treatment of dyslipidaemic patients with low plasma HDL‐cholesterol levels: a 12‐week randomized trial , 2002, Journal of internal medicine.

[44]  I. Holme,et al.  High apolipoprotein B, low apolipoprotein A-1, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study☆ , 2002 .

[45]  I. Holme,et al.  High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study , 2001, The Lancet.

[46]  G. Luc,et al.  A multicenter comparison of the effects of simvastatin and fenofibrate therapy in severe primary hypercholesterolemia, with particular emphasis on lipoproteins defined by their apolipoprotein composition. , 1992, Metabolism: clinical and experimental.

[47]  J. Hanley,et al.  The meaning and use of the area under a receiver operating characteristic (ROC) curve. , 1982, Radiology.

[48]  G. Keating,et al.  Fenofibrate , 2012, Drugs.

[49]  G. Moneta,et al.  Major Lipids, Apolipoproteins, and Risk of Vascular Disease , 2010 .

[50]  Robert Dufour,et al.  Canadian Cardiovascular Society / Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult – 2009 recommendations , 2009 .

[51]  S. Grundy,et al.  Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. , 2004, Journal of the American College of Cardiology.

[52]  K. Jablonski,et al.  Non-HDL cholesterol as a predictor of cardiovascular disease in type 2 diabetes: the strong heart study. , 2003, Diabetes care.